Melanotan II

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the 1980s and 1990s as part of a research program seeking UV-independent tanning agents that could reduce skin cancer incidence by stimulating protective melanin production without the DNA-damaging radiation that conventional tanning requires. The compound was synthesised by Dr. Mac Hadley and Dr. Victor Hruby's groups using systematic peptide structure-activity relationships to identify the minimal pharmacophore of α-MSH capable of activating melanocortin receptors with high affinity and in a stable cyclic configuration. The cyclic structure of MT-II — achieved through a lactam bridge between D-lysine at position 5 and glutamic acid at position 10 — confers substantially greater metabolic stability and receptor binding affinity compared to the linear endogenous α-MSH, making it a significantly more potent and longer-acting melanocortin receptor agonist on a molar basis.

The melanocortin receptor family comprises five receptors (MC1R through MC5R) with distinct tissue distribution and physiological roles. While the endogenous α-MSH has activity across all five receptors, its primary physiological role is at MC1R in melanocytes for pigmentation regulation. Melanotan II's cyclic structure and modified amino acid composition make it a promiscuous agonist with significant activity at MC1R, MC3R, MC4R, and MC5R — a breadth of receptor engagement that produces the complex, multi-system pharmacological profile that characterises MT-II's use.

The tanning mechanism of Melanotan II operates through MC1R activation on epidermal melanocytes. When MT-II binds to MC1R, it activates adenylate cyclase, increases intracellular cAMP, and activates MITF (microphthalmia-associated transcription factor), which drives the transcription of enzymes in the melanin biosynthesis pathway — particularly tyrosinase, TRP-1, and TRP-2 — and the organelle biogenesis pathways that produce melanosomes (the organelles in which melanin is synthesised and stored). The net result is increased synthesis of eumelanin — the brown-black, UV-absorbing form of melanin — and increased transfer of melanosomes from melanocytes to adjacent keratinocytes, producing visible skin darkening. MT-II's higher MC1R affinity relative to Melanotan I and native α-MSH means it achieves this effect with smaller doses and with a shorter time to visible pigmentation, though UV exposure is still required as a co-stimulus for optimal eumelanin production in most individuals.

The sexual arousal and erectile function effects of MT-II — arguably its most studied application after its tanning effects — are mediated through MC4R in the hypothalamus, limbic system, and brainstem. MC4R is expressed throughout the brain circuits governing sexual motivation, reward, and autonomic output. When MT-II crosses the blood-brain barrier (it does penetrate CNS, unlike Melanotan I which has much lower CNS penetration) and activates hypothalamic and limbic MC4R, it produces a centrally-driven increase in sexual desire and motivation, facilitates erection in men through autonomic mechanisms, and enhances genital arousal and lubrication in women. These effects occur regardless of prior sexual stimulation — a central mechanism rather than a peripheral vascular one — distinguishing MT-II's mechanism from PDE5 inhibitors (Viagra, Cialis), which require peripheral sexual stimulation to initiate the erectile cascade. The sexual effects typically peak 1–2 hours post-injection and may persist for 6–12 hours.

The appetite-suppressing effects of MT-II are likewise mediated through MC4R, which is the downstream receptor of the leptin-melanocortin appetite regulation axis. Leptin signalling in the hypothalamus activates POMC neurons that release α-MSH, which then activates MC4R to suppress appetite and increase energy expenditure. Direct MC4R agonism by MT-II replicates this appetite-suppressing effect and can produce meaningful reductions in food intake — a secondary effect that has attracted interest from some metabolic researchers. MC5R activation contributes to increased exocrine secretion, which may explain the increased salivation some users report, and potentially contributes to the cardiovascular effects through altered autonomic tone.

The substantial nausea associated with MT-II — particularly pronounced in first-time users at higher doses — is primarily mediated through activation of area postrema (vomiting centre) MC4R and through autonomic changes triggered by systemic melanocortin receptor activation. This nausea is dose-dependent and tends to diminish with repeated exposure as subjects develop partial tolerance. Practical management strategies include starting with very low test doses (0.1 mg), taking the injection after a meal, and lying recumbent post-injection. Pre-medication with an antiemetic such as ondansetron (4 mg orally 30–60 minutes before injection) substantially reduces nausea for most subjects.

Dermatological monitoring during any MT-II research protocol is essential because MT-II's broad melanocortin receptor activation can stimulate pigmented cell populations beyond normal melanocytes. New nevi (moles) have been reported with MT-II use, existing nevi may darken rapidly, and dysplastic (atypically appearing) nevi should be evaluated by a dermatologist before beginning any tanning peptide protocol. These changes require careful monitoring as altered nevi can occasionally be early warning signs of more concerning lesions.